Clofazimine Inhalation Suspension Fast Tracked for NTM Lung Disease
MPR,
The Food and Drug Administration (FDA) has granted Fast Track designation to clofazimine inhalation suspension (MNKD-101) for…
The Food and Drug Administration (FDA) has granted Fast Track designation to clofazimine inhalation suspension (MNKD-101) for…
Follow Summary MannKind is positioned for growth with the clofazimine inhalation suspension advancing to a Phase 2/3 study and…
Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease…
News provided by MannKind Jan 23, 2023, 6:05 AM ET Direct delivery of clofazimine to the lungs may provide a treatment option…